Specifically, to people living with chronic pain and their relevant healthcare providers.
The roll-out commences this month.
Medlab’s CEO Dr Sean Hall said: “We openly welcome this alliance with Chronic Pain Australia, we understand that pain management has to extend beyond opioids, their derivatives, and lifestyle management; new therapies such as NanaBis™ equate to more options, and together we can work on better patient outcomes.”
Chronic Pain Australia is a not-for-profit consumer-lead organisation dedicated to reducing health and social barriers faced by people living with chronic pain.
It supports over 35,000 people living with chronic pain each month and has partnered with the Australian Pain Society and Faculty of Pain Medicine to develop Australia's first National Pain Strategy.
NanaBis™ in clinical trial at Royal North Shore Hospital
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).
NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.
NanaBis™ is currently in clinical trial at Royal North Shore Hospital.
Notably, both medicines are available to Australian patients for compassionate use under the government Special Access Scheme (SAS).
Proactive caught up with Medlab last month to get an update on the company, including NRGBiotic™, a probiotic.